Medpage Today on MSN4d
FDA Adds New Warning to GLP-1 DrugsThe warning affects all treatments containing GLP-1 receptor agonists, including semaglutide ( Ozempic, Wegovy, Rybelsus ), ...
The majority of patients may safely take glucagon-like peptide 1 receptor agonists (GLP-1 RAs) before elective surgery and ...
HealthDay on MSN13h
AHA: GLP-1 RA, SGLT-2i Use Can Lower Risk for MI, Recurrent Stroke in Stroke SurvivorsFor patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor ...
News Medical on MSN2d
GLP-1, SGLT2 Drugs Cut Heart Risk for Stroke SurvivorsIn an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 ...
GLP-1 receptor agonists, originally developed for managing type 2 diabetes, have rapidly emerged as highly effective ...
GLP-1, SGLT2 medications may lower risk of future MI and repeat stroke among stroke survivors: Study
GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or ...
(NewMediaWire) - November 11, 2024 - DALLAS GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the ...
GLP-1 receptor agonists, originally developed for managing type 2 diabetes, have rapidly emerged as highly effective ...
GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...
GLP-1 receptor agonists, originally developed for managing type 2 diabetes, have rapidly emerged as highly effective ...
Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback